---
schema_version: "secwatch.filing_event.v1"
accession: "0001534969-22-000048"
form_type: "8-K"
ticker: "SERA"
cik: "0001534969"
company_name: "SERA PROGNOSTICS, INC."
filed_at: "2022-04-12T23:59:59+00:00"
generated_at: "2026-06-26T07:56:31.679081+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Sera Prognostics appoints Dr. Jane F. Barlow to Board of Directors

## Summary
- Dr. Jane F. Barlow appointed as Class I Director effective April 11, 2022; term expires at 2022 annual meeting.
- Dr. Barlow brings experience from CVS Health, Medco, and boards of ContraFect, Viracta, Point Health.
- Granted non-qualified stock option with $240,000 grant date fair value, vesting monthly over 36 months.
- Entitled to annual cash retainer of $35,000 for non-employee director service, prorated.
- Company entered into standard indemnification agreement with Dr. Barlow.

## SEC filing metadata
- accession: 0001534969-22-000048
- form_type: 8-K
- ticker: SERA
- cik: 0001534969
- company_name: SERA PROGNOSTICS, INC.
- filed_at: 2022-04-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534969/000153496922000048/0001534969-22-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534969/000153496922000048/sera-20220411.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534969-22-000048
- JSON: https://secwatch.observer/filing/0001534969-22-000048.json
- Plain text: https://secwatch.observer/filing/0001534969-22-000048.txt

## Key facts
- Executive change
  Jane F. Barlow was appointed as Class I Director at SERA PROGNOSTICS, INC..
  - Action: appointed
  - Role: Class I Director
  source text: On April 11, 2022, the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”) appointed Jane F. Barlow, M.D., MPH, MBA, effective April 11, 2022 (the “Effective Date”), as a director to the Board to serve as a Class I Director with a term expiring at the Company’s 2022 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534969/000153496922000048/0001534969-22-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.